Introduction:
The ORBIT-AF Bleeding Score [Outcomes Registry for Better Informed Treatment of Atrial Fibrillation] is used to assess the risk of bleeding in patients with Atrial Fibrillation [AF] on anticoagulation with oral anticoagulants.
Major bleeding was defined as:
i. Fatal bleeding
ii.
Symptomatic bleeding in a critical area or organ (intra-cranial, intra-spinal, intra-ocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome),
iii.
Bleeding causing a fall in haemoglobin of ≥20 g/L [≥2 g/dL] or leading to the transfusion of two or more units of whole blood or red cells.
In the original study, 93.4% of patients were treated with Warfarin and 6.6% with Dabigatran. The algorithm was also used to study the risk of bleeding in the ROCKET-AF study [- Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation].